Alk-Abello A/S (Alk-Abello A/S) Total Receivables : $133.7 Mil (As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Alk-Abello A/S Total Receivables?

Alk-Abello A/S's Total Receivables for the quarter that ended in Mar. 2024 was $133.7 Mil.

Alk-Abello A/S Total Receivables Historical Data

The historical data trend for Alk-Abello A/S's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello A/S Total Receivables Chart

Alk-Abello A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Receivables

Get a 7-Day Free Trial

97.58

107.92

102.87

123.03

130.22

Alk-Abello A/S Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Receivables	Get a 7-Day Free Trial															131.47	134.02	128.23	130.22	133.68

Alk-Abello A/S Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Alk-Abello A/S Total Receivables Related Terms

Thank you for viewing the detailed overview of Alk-Abello A/S's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Alk-Abello A/S (Alk-Abello A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello A/S (OTCPK:AKBLF) » Definitions » Total Receivables

Comparable Companies

Traded in Other Exchanges

ALKBc:UK 0OIR:UK ALK B:Denmark 4AJ0:Germany

Address

Boge Alle 6-8, Horsholm, DNK, DK-2970

Website

https://www.alk.net

Alk-Abello A/S is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication.